Introduction:
PNETs are sporadic tumors that arise from the pancreatic islet cells. They can be non-functioning and present with systemic manifestations or functioning ones, which secrete hormones resulting in characteristic symptoms. The pancreatic neuroendocrine tumor treatment includes the following, based on its hormonal secreting capabilities: chemotherapy, targeted medications, peptide receptor radionuclide therapy, hepatic treatments, surgical resection, and other treatments. Treatments in recent times have evolved, showing the importance of an individualistic management approach for malignant cancers. The pancreatic neuroendocrine tumor prognosisvaries based on the grade of tumors. For optimal results, the entire tumor should be resected. Based on the site and size of the tumor, different surgical approaches include enucleation, pancreaticoduodenectomy, distal pancreatectomy, and tumor excision. After surgery, it is important to follow up closely to identify recurrence.
How Rare Are Pancreatic Neuroendocrine Tumors?
PNETs are rare, accounting for just one to two percent of the total incidence of pancreatic neoplasms. While previously thought to be relatively rare, the incidence has risen steadily over recent decades; in 2020, it is projected that 4032 people will be diagnosed with PNETs. PNETs are heterogeneous, which makes them hard to treat, mainly because 75 percent are present at an advanced stage of the disease.
What Is the Surgical Management of Pancreatic Neuroendocrine Tumors?
Surgical management is one aspect of the key factors in treating PNETs. PNETs are a broad category of tumors because they originate from islet cells in the pancreas and have taken on various clinical characteristics. For PNETs, surgery remains the most symptomatic effective option for therapy because it could be curative. Resection significantly enhances overall survival and is specifically indicated for nonfunctioning PNETs larger than 0.5 inches. Surgical Approaches to isolated PNETs include distal pancreatectomy, pancreatoduodenectomy, and enucleation. The role of parenchymal sparing resections is evolving. In an attempt to treat tail tumors, or those affecting the tail of the organ, surgery may require a distal pancreatectomy or the removal of the tail of the pancreas. The head of the pancreas is not touched in this procedure.
In cancers of the pancreas head, the Whipple procedure or pancreaticoduodenectomy may be done wherein the tumor, along with most or all of the pancreas, is removed. When there is a spread to other parts of the body, surgery may be required to remove the cancer from that part of the body. Liver metastases are common in PNETs; in such cases, hepatectomy (surgery for removal of whole or a portion of the liver) is recommended; chemotherapy is advised for poorly differentiated tumors.
Other methods for the management of pancreatic neuroendocrine tumors:
-
Peptide Receptor Radionuclide Therapy: In PRRT, a small quantity of a radioactive substance is given through a vein along with a medication that is supposed to attach itself only to cancerous cells. Wherever the pancreatic neuroendocrine tumor cells are in the body, the medication attaches itself to the cells. This drug serves the cancer cells directly with radiation that kills them over several days to weeks.
-
Targeted Therapy: Targeted therapy treatments use medications that target specific molecules involved in the growth and survival of cancer cells. By targeting these molecules, targeted treatment can help kill cancer cells or stop their growth. Treatment might be used for certain advanced or recurrent pancreatic neuroendocrine tumors.
-
Radiofrequency Ablation: In this procedure, energy waves destroy cancer cells through a special probe containing small electrodes. The probe heats and destroys cancer cells to their death. The abdomen may be sliced, or the probe may be placed just under the skin.
-
Radiation Treatment: It involves radiation therapy, which is an intense energy beam that may kill the cells of cancer. The source may be protons, X-rays, or any other source. During radiation therapy, you lie on a table, and then a machine surrounds you. After that, that device targets certain areas of your body with radiation.
-
Chemotherapy: Chemotherapy kills the cells, usually using strong drugs. It may be used to treat pancreatic neuroendocrine tumors.
Resection of the liver can be helpful in the survival of patients who harbor metastatic PNETs.
-
Treatment Targeted at the Liver: A potential for patients with poor surgical risks
-
Systemic Therapies: Alternative treatment for those who are not good candidates for surgery.
-
Preoperative imaging must be maintained in PNETs and can be supplemented by tests like CT (computerized tomography), MRI (magnetic resonance imaging), and ultrasound. Ultrasonography may be used intraoperatively, especially in the case of insulinomas (pancreatic tumors).
The pancreatic neuroendocrine tumor islet cell tumor screening is considered.
Metastatic disease is treated initially with surgical resection when possible; for patients with extensive metastases in whom cure may not be possible, surgical therapy of the primary tumor is still often indicated. The surgical approach depends on the size of the PNET. A "wait and see" policy may be relevant in small, localized, non-functional PNETs, mainly in MEN1 (multiple endocrine neoplasia type 1). Wermer syndrome is another name for the MEN1 syndrome, which is a rare hereditary disorder that targets the endocrine glands and organs in individual cases. In selected patients, pancreas-sparing techniques represent alternatives to pancreatic resections by surgery and are more frequently used.
Surgical intervention is generally indicated in patients with low-grade, resectable metastatic disease; however, there is also evidence that palliative resection of the primary tumor improves survival in those with unresectable hepatic metastases. Surgery is crucial in managing PNET and offers curative treatment. Surgical decision-making is part of interdisciplinary care for these cancers since a complete resection is required to achieve a cure.
The treatment of the primary lesion is surgical, with techniques such as parenchyma-sparing surgery based on the patient's condition, preoperative work-up, and tumor functionality. Surgical resection combined with regional lymph node dissection is considered the standard of care for localized PNETs, but because metachronous liver metastases are possible, postoperative monitoring is required.
Conclusion:
The pancreatic neuroendocrine tumor survival rate depends on the kind, grade, and presence or absence of metastases. Surgical care for PNETs is evolving. The techniques used in their management depend on the patient's status and tumor characteristics. Surgery remains one of the primary treatment methods for PNETs and allows for potential recovery and alleviation of symptoms.
